

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-331 deleted, without prejudice.

332. (previously presented) A method of treating cancer in a mammal having a tumor comprising administering systemically to said mammal a Newcastle Disease Virus in an amount sufficient to cause tumor regression.

333. (previously presented) A method as in claim 332 wherein said tumor is selected from the group consisting of: lung carcinoma, breast carcinoma, prostate carcinoma, colon adenocarcinoma, cervical carcinoma, endometrial carcinoma, ovarian carcinoma, bladder carcinoma, Wilm's tumor, fibrosarcoma, osteosarcoma, melanoma, synovial sarcoma, neuroblastoma and glioblastoma.

334. (previously presented) A method as in claim 332 wherein said tumor is a colon adenocarcinoma.

335. (previously presented) A method as in claim 332 wherein said tumor is a melanoma.

336. (previously presented) A method as in claim 332 wherein said tumor is a neuroblastoma.

337. (previously presented) A method as in claim 332 wherein said Newcastle Disease Virus is strain Mass MK107.

338. (previously presented) A method as in claim 332 wherein said Newcastle Disease Virus is strain 73-T.

339. (previously presented) A method as in claim 332 wherein said administering systemically is administering in multiple doses.

340. (previously presented) A method as in claim 332 wherein said administering systemically is administering by the intravenous route.

341. (previously presented) A method as in claim 332 wherein said administering systemically is administering by the intraperitoneal route.

342. (previously presented) A method as in claim 332 wherein the amount of Newcastle Disease Virus administered systemically is about  $4 \times 10^{10}$  to  $4 \times 10^{12}$  PFU/kg.

343. (previously presented) A method of treating cancer in a mammal having a tumor comprising administering systemically to said mammal more than one dose of a Newcastle Disease Virus.

344. (previously presented) A method as in claim 343 wherein said tumor is selected from the group consisting of lung carcinoma, breast carcinoma, prostate carcinoma, colon adenocarcinoma, cervical carcinoma, endometrial carcinoma, ovarian carcinoma, bladder carcinoma, Wilm's tumor, fibrosarcoma, osteosarcoma, melanoma, synovial sarcoma, neuroblastoma and glioblastoma.

345. (previously presented) A method as in claim 343 wherein said tumor is a colon adenocarcinoma.

346. (previously presented) A method as in claim 343 wherein said tumor is a melanoma.

347. (previously presented) A method as in claim 343 wherein said tumor is a neuroblastoma.

348. (previously presented) A method as in claim 343 wherein said Newcastle Disease Virus is strain Mass MK107.

349. (previously presented) A method as in claim 343 wherein said Newcastle Disease Virus is strain 73-T.

350. (previously presented) A method as in claim 343 wherein the amount of Newcastle Disease Virus administered systemically is an amount sufficient to cause tumor regression.

351. (previously presented) A method as in claim 343 wherein the amount of Newcastle Disease Virus administered systemically is about  $4 \times 10^{10}$  to  $4 \times 10^{12}$  PFU/kg.

352. (previously presented) A method as in claim 343 wherein the amount of Newcastle Disease Virus administered systemically is about  $4 \times 10^9$  PFU/kg.

353. (previously presented) A method as in claim 343 wherein said administering systemically is administering by the intravenous route.

354. (previously presented) A method as in claim 343 wherein said administering systemically is administering by the intraperitoneal route.

355. (previously presented) A method of treating cancer in a mammal having a tumor comprising administering intravenously to said mammal more than one dose of a Newcastle Disease Virus in an amount sufficient to cause tumor regression.